Zobrazeno 1 - 10
of 229
pro vyhledávání: ''
Autor:
Jean-Marc Phelip, Bernard Flourié, Pauline Veyrard, Gilles Boschetti, Martin Killian, Anne-Emmanuelle Berger, Xavier Roblin, Stéphane Paul, Nicolas Williet, Capucine Genin, Louis Waeckel, Stéphane Nancey
Publikováno v:
Inflammatory Bowel Diseases. 28:720-727
Background In cases of loss of response due to mechanistic failure under antitumor necrosis factor agents, it is recommended to switch to another class of biologics. Two different strategies were compared in patients with inflammatory bowel disease (
Autor:
George Kolios, Eirini Zacharopoulou, Nikolas Dovrolis, Vasilleios Xourafas, Spyridon Michopoulos, G Michalopoulos, Marilena M. Bourdakou, G Kokkotis, Evanthia Zampeli, Maria Gazouli, George V. Papatheodoridis, Michalis Gizis, Gerasimos J. Mantzaris, Nikos Viazis, Giorgos Bamias, Maria Tzouvala, Ioannis Papaconstantinou
Publikováno v:
Inflammatory Bowel Diseases. 28:87-95
Background Improving treatment outcomes with biological therapy is a demanding current need for patients with inflammatory bowel disease. Discovery of pretreatment prognostic indicators of response may facilitate patient selection and increase long-t
Publikováno v:
Inflamm Bowel Dis
Autor:
Suresh Venkateswaran, Thomas D. Walters, Subra Kugathasan, Cary G. Sauer, Joelynn Dailey, James Markowitz, Marian Pfefferkorn, Neal S. Leleiko, Yael Haberman, Jeffrey S. Hyams, Brendan M. Boyle, Michael Brimacombe, Robert N. Baldassano, Lee A. Denson, David R. Mack, Joel R. Rosh, Angela Mo, Anne M. Griffiths, Greg Gibson, Ashish S. Patel, Sapana Shah
Publikováno v:
Inflamm Bowel Dis
Background Develop a clinical and biological predictive model for colectomy risk in children newly diagnosed with ulcerative colitis (UC). Methods This was a multicenter inception cohort study of children (ages 4-17 years) newly diagnosed with UC tre
Autor:
Andrea S. Laimbacher, Kirstin Atrott, Marcin Wawrzyniak, Roberto Manzini, D Lissner, Michael Scharl, Marianne R. Spalinger, Matthias Turina, Britta Siegmund, Gerhard Rogler, Andreas Rickenbacher, Marlene Schwarzfischer, Silvia Lang, Petr Hruz
Publikováno v:
Inflammatory Bowel Diseases. 27:1986-1998
Background Vedolizumab is a widely used and safe therapy in inflammatory bowel disease, particularly in ulcerative colitis (UC), making it a promising candidate for enhanced efficacy by combining it with additional immunomodulatory medications. In th
Autor:
Jessica R. Allegretti, Emma L. McClure, Matthew J. Hamilton, Andrew Canakis, Beth-Ann Norton, Jenna Marcus, Punyanganie S. de Silva, Sonia Friedman, Joshua R. Korzenik, Rachel W. Winter
Publikováno v:
Inflammatory Bowel Diseases. 27:2031-2033
Publikováno v:
Inflamm Bowel Dis
Background Nontraditional combination of existing therapies is often the only option to avoid surgery in refractory inflammatory bowel disease (IBD) patients. We aim to assess the efficacy and safety of concomitant use of 2 biologic therapies or comb
Autor:
Manying Li, Baili Chen, Gaoshi Zhou, Rui Feng, Yun Qiu, Xiaojun Zhuang, Minhu Chen, Tong Li, Zhirong Zeng, Shenghong Zhang, Yao He, Zhenyi Tian
Publikováno v:
Inflammatory Bowel Diseases. 26:1636-1647
Background Gut microbiota dysbiosis is associated with the occurrence and development of Crohn disease (CD). Currently, infliximab (IFX) is used more and more to treat CD; however, gut microbiota alterations during IFX therapy are variable and someti
Autor:
Amanda Ricciuto, Anne M. Griffiths, Firas Rinawi, Eileen Crowley, Karen Frost, Thomas D. Walters, Peter C Church
Publikováno v:
Inflammatory Bowel Diseases. 27:1079-1087
Background Data on the association between early postinduction serum adalimumab (ADA) trough levels (TLs) and objective outcomes are scarce. The aim of this study was to investigate whether early ADA TLs at weeks 4 and 8 are associated with clinical
Autor:
Elisabeth M. Davis, Katherine F. Simpson, Brian Claggett, Jacqueline Perrigoue, Eric U. Yee, Xueyan Guo, Felicia D. Allard, Ilyssa O. Gordon, Mark T. Osterman, Matthew A. Ciorba, Kelli L. VanDussen, Thaddeus S. Stappenbeck, Bincy Abraham, Julia J. Liu, Bo Shen, Sarah C. Glover, Katherine Li
Publikováno v:
Inflamm Bowel Dis
Background Therapeutic efficacy of biologics has remained at about 50% for 2 decades. In Crohn’s disease (CD) patients, we examined the predictive value of an epithelial cell biomarker, ileal microvillar length (MVL), for clinical response to ustek